EGFR and breast carcinoma: Rao et al., [54] reported that 33% of triple negative phenotype breast carcinomas show expression of basal markers (CK5/6 and/or over-expression of EGFR) and that “Triple negative” status cannot be used as a surrogate for “basal marker expression”.